Global emergence of resistance to fluconazole and 1 voriconazole in Candida parapsilosis in tertiary hospitals in 2 3 Spain during the COVID-19 pandemic Oscar Zaragoza^{1,2*}, Laura Alcázar-Fuoli^{1,2}, Nuria Trevijano-Contador¹, Alba Torres-4 5 Cano¹, Cristina Carballo-González¹, Mireia Puig-Asensio^{3,4}, María Teresa Martín-Gómez⁵, Emilio Jiménez-Martínez³, Daniel Romero⁵, Francesc Xavier Nuvials⁶, 6 Roberto Olmos-Arenas⁷, María Clara Moretó-Castellsagué⁷, Lucía Fernández-7 Delgado⁷, Graciela Rodríguez-Sevilla⁷, María-Mercedes Aguilar-Sánchez⁷, Josefina 8 Avats-Ardite⁷, Carmen Ardanuy-Tisaire⁷, Isabel Sanchez-Romero⁸, María Muñoz-9 Algarra⁸, Paloma Merino-Amador⁹, Fernando González-Romo⁹, Gregoria Megías-10 Lobón¹⁰, Jose Angel García-Campos¹⁰, María Ángeles Mantecón-Vallejo¹⁰, Maria 11 Teresa Durán-Valle¹¹, Arturo Manuel Fraile-Torres¹¹, María Pía Roiz-Mesones¹², Isabel 12 Lara-Plaza¹², Ana Perez de Ayala¹³, María Simón-Sacristán¹⁴, Ana Collazos-Blanco¹⁴, 13 Teresa Nebreda-Mavoral¹⁵. Gabriel March-Roselló¹⁵. 14 15 16 1) Mycology Reference Laboratory. National Centre for Microbiology. Instituto de Salud 17 Carlos III. Carretera Majadahonda-Pozuelo, Km2. Majadahonda 28220. Madrid. Spain. 18 2) Center for Biomedical Research in Network in Infectious Diseases 19 (CIBERINFEC-CB21/13/00105), Instituto de Salud Carlos III, Madrid, Spain. 20 3) Department of Infectious Diseases, Hospital Universitari de Bellvitge-Institut 21 d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain. 22 4) Center for Biomedical Research Network in Infectious Diseases (CIBERINFEC; 23 24 25 26 27 CB21/13/00009), Instituto de Salud Carlos III, Madrid, Spain 5) Department of Microbiology, Vall D'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain. 6) Intensive Care Unit, Vall D'Hebron University Hospital, Universitat Autònoma de Barcelona, Spain. 28 7) Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain. 29 8) Microbiology Department, Hospital Universitario Puerta de Hierro, Majadahonda, 30 Madrid. Spain: 31 9) Microbiology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain; 32 Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain; 33 Department of Medicine, Universidad Complutense School of Medicine, Madrid, Spain. 34 10) Department of Clinical Microbiology. Hospital Universitario de Burgos 35 11) Microbiology and Parasitology Department. Hospital Universitario de Móstoles 36 37 12) Microbiology Department, Marqués de Valdecilla Universitary Hospital, Santander. Cantabria. España. Instituto de Investigación Valdecilla (IDIVAL). 38 13) Microbiology Unit. Universitary Hospital 12 de Octubre. Madrid, Spain 39 14) Microbiology and Parasitology Department. Hospital Central de la Defensa Gómez Ulla. 40 Madrid, Spain. 41 15) Microbiology and Immunology Unit. Universitary Clinic Hospital of Valladolid 42 43 *Corresponding author: Oscar Zaragoza 44 45 Email for correspondence: ozaragoza@isciii.es 46 47 Running title: FLZ resistance in С. parapsilosis

48 **ABSTRACT**

49

50 Background: Candida parapsilosis is a frequent cause of candidemia 51 worldwide. Its incidence is associated with the use of medical implants, such as 52 central venous catheters or parenteral nutrition. This species has reduced 53 susceptibility to echinocandins and is susceptible to polyenes and azoles. 54 Multiple outbreaks caused by fluconazole non-susceptible strains have been 55 reported recently. A similar trend has been observed among the C. parapsilosis isolates received in the last two years at the Spanish Mycology Reference 56 57 Laboratory.

58

59 **Methods:** Yeast were identified by molecular biology and antifungal 60 susceptibility testing was performed using EUCAST protocol. *ERG11* gene was 61 sequenced to identify resistance mechanisms, and typification was carried out 62 by microsatellite analysis.

63

64 **Results:** We examined the susceptibility profile of the *C. parapsilosis* isolates 65 available at our Reference Laboratory since 2000 (around 1,300 strains). 66 During the last two years, the number of isolates with acquired resistance to 67 fluconazole and voriconazole has increased in at least eight different Spanish 68 hospitals. Typification of the isolates revealed that some prevalent clones had 69 spread through several hospitals of the same geographical region. One of these 70 clones was found in hospitals from the region of Catalonia, another in hospitals 71 from Madrid and Burgos, and two other different genotypes from Santander.

72

Conclusions: Our data suggests that the epidemiological situation caused by the COVID-19 pandemic might have induced a selection of fluconazoleresistant *C. parapsilosis* isolates that were already present at the hospitals. Further measures must be taken to avoid the establishment of clinical outbreaks that could threaten the life of infected patients.

78

79 Keywords: Candida parapsilosis; fluconazole; voriconazole; antifungal
80 resistance, outbreaks.

81

82

83 INTRODUCTION

84

85 Candida parapsilosis is an opportunistic pathogenic yeast able to cause 86 invasive diseases such as candidemia. Worldwide, it is the third cause of 87 bloodborne yeast infection after C. albicans and C. glabrata, although in some 88 countries, its incidence is higher and above C. glabrata [1-4]. Neonates, as well 89 as indwelling parenteral nutrition and central nervous catheters have been 90 associated to a higher risk of infection [5, 6]. Besides sporadic infections, C. 91 parapsilosis is well known to cause nosocomial outbreaks through direct and 92 indirect contact via the hands of health care workers and through contaminated 93 patient care equipment.

94 Candida parapsilosis exhibits a reduced natural in vitro susceptibility to 95 echinocandins [7], so the main therapeutic options for invasive infections due to 96 this species are the triazoles, mainy fluconazole or, alternatively, polyenes. 97 Acquired resistance to fluconazole in C. parapsilosis is a rare phenomenon, 98 being less than 5% of isolates in different epidemiological studies [2, 7-10]. In 99 recent years, however, a steady increase of resistance has been observed 100 worldwide, mostly in the context of nosocomial outbreaks [11-20]. In many 101 cases, these outbreaks are monoclonal, and are associated to mutations in 102 ERG11 (mainly with the Y132F mutation), overexpression of efflux pumps (as 103 Mdr1 and Cdr1) and mutations in *MRR1*, which encodes a transcription factor 104 that regulates the expression of some efflux pumps [11-13, 16, 18, 21, 22].

105

106 The National Centre for Microbiology from Instituto de Salud Carlos III (CNM-107 ISCIII, Madrid, Spain) acts as a national reference center for clinically isolated 108 fungi, providing services such as genotyping and confirmation of antifungal 109 susceptibility profiles by the EUCAST standardized methodology. Since 2020 a 110 significant increase in the number of fluconazole non-susceptible (FNS) C. 111 parapsilosis isolates received was noted, most of them coming from tertiary 112 hospitals across the country reporting to have a strong epidemiological 113 suspicion of ongoing outbreaks.

114

The aim of this work was to describe the antifungal susceptibility profile of all 115 116 the C. parapsilosis isolates received in the Spanish Mycology Reference Laboratory (SMRL) since 2000 to get insights about susceptibility profile and 117 118 appearance of resistance in this species. Typing analysis confirmed genetic 119 relatedness between isolates and suggested that in Spain there could be an 120 expansion of *C. parapsilosis* resistant isolates among tertiary care hospitals. 121 The fact that this expansion overlaps with the impact of the COVID-19 122 pandemic, highlights a worrisome situation in which resistance to azoles in C. 123 parapsilosis could be emerging worldwide.

124

125

126 MATERIAL AND METHODS

127

128 Media and strains identification

The isolates were primarily isolated, identified and screened for fluconazole non-susceptibility at the local laboratories following the routine methodologies of each center. Isolates sent to the CNM-ISCIII since 2000 and identified as *C. parapsilosis* were subcultivated onto Sabouraud solid or liquid medium. Identification was confirmed by sequencing the internal transcribed spacer 1 (ITS1) and ITS2 regions from the ribosomal DNA as previously in [23].

135

136 Antifungal susceptibility

Antifungal susceptibility testing was performed following EUCAST protocol 137 138 (RPMI 1640 medium (Merck, Sigma-Aldrich) buffered with MOPS (Merck, Sigma-Aldrich) at pH 7 and supplemented with 2% glucose (Merck, Sigma-139 140 Aldrich), [24]). The following antifungals were tested in the concentration range 141 indicated in brackets: Amphotericin B (AmB, Merck, Sigma-Aldrich, 16-0.03 142 mg/L), flucytosine (64-0.125 mg/L), fluconazole (FLC, Merck, Sigma-Aldrich, 64-143 0.125 mg/L), itraconazole (ITZ, Janssen Pharmaceutical Research and 144 Development, 8-0.016 mg/L), voriconazole (VOR, Pfizer Pharmaceutical Group, 8-0.016 mg/L), posaconazole (POS, Merck, Sigma-Aldrich, 8-0.016 mg/L), 145 146 isavuconazole (ISV, Pfizer Pharmaceutical Group, 8-0.016 mg/L), caspofungin (CSP, Merck, Sigma-Aldrich, 16-0.016 mg/L), micafungin (MICA, Astellas 147 148 Pharma Inc, 2-0.004 mg/L) and anidulafungin (ANID, Pfizer Pharmaceutical 149 Group, 4-0.008 mg/L). The Minimal inhibitory concentration (MIC) was defined as the concentration that caused 50% of growth inhibition compared to the 150 control well without antifungal, except for amphotericin B (90%). Strains were 151 152 categorized as susceptible (S), resistant (R) or intermediate (I, susceptible, 153 increased exposure) following the breakpoints established by EUCAST (see 154 https://www.eucast.org/astoffungi/clinicalbreakpointsforantifungals, document from February 4th, 2020). Control strains C. parapsilosis ATCC 22019 and C. krusei ATCC 6258 155 156 were included in all the assays.

157

158 Sequencing of the ERG11 gene.

To identify mutations at the *ERG11* gene, different primers were designed (see table 1). The whole gene was amplified using oligonucleotides 01_F and 02_R using the following PCR conditions: 94°C for 2 min and 35 cycles of amplification (94°C for 30 s, 56°C for 45 s and 72°C for 2 min) followed by a 1 final cycle of 5 min of 72°C.

The PCR products were purified with ExoStart kit. Sanger sequencing was performed using all the oligonucleotides described in table 1, and analyzed with Seqman software (DNA Lasergene 12 package).

167

168 Microsatellite typing

A panel of four short tandem repeat (STR) markers was used for genotyping the 169 170 C. parapsilosis isolates. Three trinucleotide repeat and one hexanucleotide repeat markers described by Diab-Elschahawi [25] were independently 171 172 amplified by PCR. Amplifications reactions were performed in a final volume of 173 20 µl for markers 3A, 3B and 6A, containing 1 ng of genomic DNA, 0.5 µM 174 amplification primers, 120 µM of dNTPS, 1.25 mM MgCl₂ and 1 U of Amplitaq[™] 175 DNA (Applied Biosystems). The PCR conditions used were: initial 176 denaturalization for 5 min at 95 °C, followed by 30 cycles of 15 s of 177 denaturalization at 95 °C, 1 min of annealing at 62 °C, and 1 min of extension at 178 72 °C. A final incubation of 7 min at 72 °C was included in the protocol. The PCR conditions were optimized for the "3C" marker. In this case, amplifications 179 180 reactions were performed in a final volume of 50 µl, containing a 1 ng of DNA, 0.2 µM amplification primers, 0.05 mM of dNTPS, 0.3 mM MgCl₂ and 1 U of 181 182 Amplitag[™] DNA (Applied Biosystems). PCR conditions for 3C marker were as

follows: initial denaturalization for 5 min at 94 °C, followed by 35 cycles of 30 s 183 of denaturalization at 94 °C, 45 s of annealing at 60 °C, and 1 min of extension 184 at 72 °C followed of 5 min at 72 °C. Then, 10 µl of the amplification products 185 were put on PCR Plate 96 semi-skirted (Eppendorf) and purified with AMpure 186 187 XP (Beckman Coulter) using SPRI beads technology in an Eppendorf ep Motion 5075 (Eppendorf). Finally, a 1 µl aliquot of PCR product was added to a 9 µl of 188 189 Formamide and to a 1 µl of internal size marker GeneScan[™] 500 ROX[™] 190 (Applied Biosystems). After denaturalization of the samples at 95 °C for 3 min 191 and rapid cooling to 4 °C, they were run onto a AB3730XL DNA analyzer 192 (Applied Biosystems). Allele sizes analysis was performed with the Peak 193 scanner software (Applied Biosystems) and according the internal lane size standard GeneScan[™] 500 ROX[™]. 194

195

Similarities between genotypes were visualized by constructing a minimum
spanning tree using InfoQuest FP, version 4.5 (Applied Maths, St.-MartensLatem, Belgium), treating the data as categorical information.

199

200 Data analysis and Statistics

MIC analysis was performed with SPSS software. For each year, the distribution of MICs was reported. We also calculated the geometric mean of the MICs values, the median, and the minimal and maximal values of the distributions.

205

206

207 RESULTS AND DISCUSSION

208

209 We collected all the isolates available at our laboratory (SMRL), and analysed 210 the evolution of the antifungal susceptibility pattern from 2000 to 2021. A total of 211 1,301 isolates were studied. As shown in table 1, resistance to fluconazole 212 remained low (3-7%) among the isolates from our collection until 2016. 213 However, a dramatic change in this resistance rate among the isolates received 214 at the Reference Laboratory was noted thereafter, being particularly notable 215 from 2019 onwards. Throughout the latter period, the percentage of fluconazole 216 resistance significantly increased (27% in 2019, around 60% in 2020 and 2021,

see table 2) as compared to previous years. This trend was also observed for
voriconazole (Table 3). Before 2019, the voriconazole resistance rate was
below 2%, but since 2020, the percentage of susceptible increased exposure (I,
MIC = 0.25 mg/L) and resistant strains (MIC>0.25 mg/L) increased up to around
60% among the strains received at the laboratory.

222

223 Regarding itraconazole and posaconazole, there was a slight trend to higher 224 MICs, but they were still categorized as susceptible (Table 4 and 5). Only three 225 isolates were fully resistant to fluconazole, voriconazole, itraconazole and 226 posaconazole. For isavuconazole, although there are not breakpoints to define 227 resistant strains, an increase in the MICs among the isolates received since 228 2020 was found. The isavuconazole modal MIC rose from 0.016 mg/L before 229 2020 to 0.06 mg/L later on (table 6), similarly to what was observed for 230 itraconazole and posaconazole.

231

232 The presence of *ERG11* mutations in fluconazole non-susceptible isolates was 233 investigated. The ERG11 gene of 230 strains from 2020 and 2021, including S 234 (n=34), I (susceptible, increased exposure, n=7) and R (n=189) strains to FLC 235 was sequenced. The ERG11 gene was found to be wild-type in all the 236 susceptible strains, and in 4.8% of the FNS isolates Among the latter (n=11), 237 one strain was also susceptible increased exposure (I) and six resistant to 238 voriconazole. The remaining fluconazole-resistant isolates (n=178, 95.2%) harbored the Y132F mutation, which has already been associated to FLC 239 240 resistance in C. parapsilosis (Table 7). In addition, we found that one of the 241 resistant isolates harbored the K143R mutation in ERG11 gene, which has 242 been detected in azole non-susceptible strains causing monoclonal outbreaks 243 in India [26] and also in combination with the Y132F mutation [11]. This 244 mutation has also been associated with pan-azole resistance in C. tropicalis 245 [27]. Another strain harbored the G458S mutation, which has also been related 246 to azole resistance in Candida parapsilosis [4, 28]. Finally, many isolates 247 harbored the R398I (data not shown), but this mutation was also found in 248 several susceptible isolates, which suggest that it is not related to FLZ 249 resistance.

Interestingly, in up to 35% of the FNS strains, the Y132F substitution was found 251 252 in heterozygosis. Thus, we analysed if the triazole MIC distribution differed 253 among homozygous or heterozygous strains. We observed that strains that 254 harbored the Y132F mutation in homozygosis had higher MICs to fluconazole 255 (Geometric Mean = 26.1 mg/L) compared to those strains carrying the mutation 256 in heterozygosis (Geometric Mean = 12.5). A similar situation was found for 257 voriconazole (GM of heterozygous strains = 0.39 mg/L vs GM for homozygous 258 strains = 0.5 mg/L). The Y132F substitution did not have a significant influence 259 on the susceptibility to isavuconazole, posaconazole and itraconazole. 260 Moreover, for these three antifungals, the Y132F mutation in homozygosis 261 tended to result in lower GM than in heterozygous strains (table 8).

262

263 To investigate if there was any genetic correlation between the FNS strains, we 264 performed a microsatellite-based genotyping of 256 C. parapsilosis (from 2019, 265 2020 and 2021) isolates from 220 different patients and 8 environmental 266 strains, including 81 susceptible, 6 susceptible increased exposure and 168 267 resistant isolates. Among the susceptible isolates, we included strains from the 268 same hospitals that had resistant strains, but also others not related to these 269 outbreaks. Microsatellite genotyping identified 118 different genotypes. The 270 relationship between the obtained genotypes is illustrated in Fig. 1 and 271 supplemental table 1.

272

As compared to the FNS isolates, the genotypic variability was greater among fluconazole-susceptible strains, what could be attributed, in part to the fact that most of the susceptible strains were recovered from unrelated cases.

276

277 Remarkably, in the case of contemporary resistant isolates there was a 278 markedly well-defined geographical distribution of genotypes. Genotype 10 was 279 found among strains of two hospitals from the area of Barcelona (Bellvitge and 280 Vall d'Hebron Hospitals), and in an isolate from 2019 stored in the collection 281 and recovered in another center located in the metropolitan area of Barcelona. 282 These two hospitals also shared the closely related genotype 12. Neither 283 genotype 10, nor genotype 12 were found in centers from other regions in 284 Spain. Genotype 96 was found to be highly prevalent among isolates obtained

285 from centers located in Madrid and in Burgos. Genotype 95, despite being 286 much less prevalent, was identified in two centers of the Madrid metropolitan 287 area. Genotypes 67 and 75 were found exclusively in a hospital at the north of Spain (Santander), geographically distant from Madrid and Barcelona. 288 289 Additionally, fluconazole susceptible strains isolated in the context of another 290 nosocomial outbreak (Universitary Clinic Hospital from Valladolid) were 291 received, displaying genotypes clearly different from the abovementioned and 292 closely related to each other (genotypes 45 to 50). A geographical distribution 293 of the genotypes of the resistant strains is shown in figure 1.

294

A minimum spanning tree was built, showing that some genotypes have evolved by spontaneous changes in one of the microsatellite markers. The microsatellite analysis showed a distribution of clades that grouped by geographic origin, with resistant strains clustering together (Figure 2).

299

300 Our work shows a significant increase in the number of *C. parapsilosis* resistant 301 to fluconazole and voriconazole received at the SMRL from several Spanish 302 hospitals and arising in a relatively short period. This isolates seem to be part of 303 outbreaks that have emerged almost simultaneously in distant cities, and that 304 can be attributed to clones that are shared almost exclusively among 305 geographically close related centers. From these data it cannot be inferred a 306 generalized increment in the fluconazole resistance among Spanish isolates of 307 C. parapsilosis since it is not mandatory to inform about all the infections 308 caused by these species. It should be noted that another outbreak of FNS C. 309 parapsilosis has been recently described in the Balearic Islands (Son Espases 310 Hospital) [29], which supports the hypothesis that fluconazole resistant strains 311 from C. parapsilosis may have emerged and spread in Spain in the last two 312 years. All together, our data is in sharp contrast to what have being described in 313 the several former epidemiological studies that have been carried out in Spain 314 [6, 7, 30, 31], suggesting a new and worrisome change in the epidemiological 315 incidence of FNS C. parapsilosis strains.

316

Recent emergence of FNS isolates in *C. parapsilosis* has been described in other countries in the literature [11-20], so our data supports that the increase of

azole resistance in *C. parapsilosis* might be a global problem. In this study, the
majority of resistant isolates harbored the Y132F mutation, which has been
largely associated in the literature with the appearance of clonal outbreaks.
However, we also detected a few isolates that did not have this mutation. For
this reason, further studies should be performed to describe all the resistance
mechanisms circulating among Spanish hospitals.

325

326 At the moment, the reasons for the increase in the incidence of azole-resistant 327 C. parapsilosis strains in Spain are unknown, but we hypothesized that this 328 phenomenon may be related to the negative impact that the COVID-19 329 pandemic has had in Spanish hospitals for several reasons. First, there is a 330 clear temporal correlation between the increase in the number of resistant 331 isolates received at the reference laboratory and clinical impact of the 332 pandemic. Second, the COVID-19 pandemic has resulted in a severe 333 overcrowding of hospitals, and in particular, of Intensive Care Units, along with 334 the necessity of recruiting large numbers of healthcare professionals that were 335 not properly trained in infection control measures. Third, during the pandemic 336 there were changes in personal protective equipment use and the same gloves 337 could have been used between patients [32, 33]. This might have increased the 338 risk of cross-transmission between patients and caused hospital outbreaks. 339 Furthermore, during the pandemic, there has been a significant transfer of 340 patients between different hospitals, which might have contributed to the 341 dispersion of resistant clones between clinical tertiary centres. A similar 342 situation has been described in multicenter studies in India [26], which 343 highlights the ability of FNS isolates to spread and colonize hospital 344 environments. Interestingly, some of the analyzed samples in our work were 345 isolated from environmental origin in the hospital and were also found in clinical 346 samples from the same center. This correlation suggests that C. parapsilosis 347 clones might have colonized the hospital surfaces, which increases the risk of 348 recirculating among patients along the time and, in parallel, increases the risk of 349 invasive infections among the most fragile ones. Previous studies, in fact, have 350 shown, not only an increase incidence of C. parapsilosis infections in COVID-19 patients [34], but also other fungal diseases, such as Covid Associated 351

Pulmonary Aspergillosis (CAPA) [35-37], mucormycosis [38-40] and *Candida*infections [41, 42] (see reviews in [43, 44]).

354

355 The impact of the COVID-19 pandemic and clinical management of the patients 356 does not fully explain why there has been a selection of azole-resistant strains, 357 and why these genetically different resistant strains have emerged almost 358 simultaneously in distant places across Spain. An increase in the use of 359 antimicrobials has been reported since the appearance of the COVID-19 360 pandemic in some geographical regions [45]. Among azoles, an increase in the 361 use of echinocandins and voriconazole has been reported [45], which might 362 have favoured the selection of fluconazole and voriconazole-resistant C. 363 parapsilosis. Another possibility is that resistance to azoles affects virulence 364 traits. In this sense, it has been described that C. parapsilosis strains harboring 365 the Y132F mutation in *ERG11* have reduced ability to form biofilms [11], which 366 rises the hypothesis that these strains have a higher ability to spread and 367 disseminate. Furthermore, several studies have associated the incidence of 368 resistant strains with higher mortality of the patients [11, 28], which warrants 369 further studies on the virulence of FLZ non-susceptible *C. parapsilosis* strains. 370 In our case, the clinical management of the patients might have contributed to 371 the selection of pre-existing resistant clones circulating in the hospitals previous 372 to the COVID-19 pandemic [46]. In our case, this idea is supported by the fact 373 that we identified that some of the resistant clones were already present in our collection in samples from 2019. For these reason, it is required to develop 374 375 future research lines to investigate the genetic proximity of the resistant 376 isolates, and compare them not only between different hospitals, but also to 377 those described in different countries.

378

Despite the epidemiological limitations and interpretations of our work, we believe that the data herein presented is an indicator of an emerging clinical problem, that is, the selection of azole-resistance in *C. parapsilosis* during the COVID-19 pandemic. We also would like to highlight that the increase in FLZresistant isolates in tertiary hospitals in Spain is agreement with the worldwide context, where an increasing number of outbreaks is being reported. We encourage the clinical community to investigate the presence of these clones in

the hospital environment, as well as to make an effort to perform susceptibility testing in strains from non-invasive origin (colonization, isolated from hospital surfaces, etc) and to design specific measures to prevent the expansion of the associated resistance mechanisms.

390

391 Acknowledgements and Funding

392

O.Z. was funded by grants SAF2017-86912-R and PID2020-114546RB-I00
from the Spanish Ministry for Science and Innovation. This work was also
funded by the National Centre for Microbiology (Instituto de Salud Carlos III)
through the Surveillance program of Antifungal Resistance and the Center for
Biomedical Research in Network in Infectious Diseases (CIBERINFECT
CB21/13/00105 (OZ and LAF) and CB21/13/00009 (M.P-A). L.A-F. was
supported by Fondo de Investigación Sanitaria (MPY 117/18 and MPY 305/20).

401 **Conflict of interest**

- 402 The authors have no conflict of interest to declare
- 403
- 404
- 405

406 **REFERENCES**

- 407
- Toth R, Nosek J, Mora-Montes HM, et al. *Candida parapsilosis*: from
 Genes to the Bedside. Clin Microbiol Rev 2019; 32(2).
- Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty
 Years of the SENTRY Antifungal Surveillance Program: Results for
 Candida Species From 1997-2016. Open Forum Infect Dis 2019; 6(Suppl
 1): S79-S94.
- 414 3. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the
 415 epidemiological landscape of invasive candidiasis. J Antimicrob
 416 Chemother 2018; 73(suppl_1): i4-i13.
- 417 4. Arastehfar A, Lass-Florl C, Garcia-Rubio R, et al. The Quiet and
 418 Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens. J
 419 Fungi (Basel) 2020; 6(3).

- 420 5. Yamin DH, Husin A, Harun A. Risk Factors of *Candida parapsilosis*421 Catheter-Related Bloodstream Infection. Front Public Health 2021; 9:
 422 631865.
- 423 6. Puig-Asensio M, Padilla B, Garnacho-Montero J, et al. Epidemiology and
 424 predictive factors for early and late mortality in Candida bloodstream
 425 infections: a population-based surveillance in Spain. Clin Microbiol Infect
 426 2014; 20(4): O245-54.
- Guinea J, Zaragoza O, Escribano P, et al. Molecular identification and
 antifungal susceptibility of yeast isolates causing fungemia collected in a
 population-based study in Spain in 2010 and 2011. Antimicrob Agents
 Chemother 2014; 58(3): 1529-37.
- 431 8. latta R, Caggiano G, Cuna T, Montagna MT. Antifungal susceptibility
 432 testing of a 10-year collection of *Candida* spp. isolated from patients with
 433 candidemia. J Chemother 2011; 23(2): 92-6.
- 434 9. Ziccardi M, Souza LO, Gandra RM, et al. *Candida parapsilosis* (sensu
 435 lato) isolated from hospitals located in the Southeast of Brazil: Species
 436 distribution, antifungal susceptibility and virulence attributes. Int J Med
 437 Microbiol 2015; 305(8): 848-59.
- 438 10. Battistolo J, Glampedakis E, Damonti L, et al. Increasing Morbidity and
 439 Mortality of Candidemia over One Decade in a Swiss University Hospital.
 440 Mycoses 2021.
- 441 11. Arastehfar A, Daneshnia F, Hilmioglu-Polat S, et al. First Report of
 442 Candidemia Clonal Outbreak Caused by Emerging Fluconazole443 Resistant *Candida parapsilosis* Isolates Harboring Y132F and/or
 444 Y132F+K143R in Turkey. Antimicrob Agents Chemother 2020; 64(10).
- 445 12. Choi YJ, Kim YJ, Yong D, et al. Fluconazole-Resistant *Candida*446 *parapsilosis* Bloodstream Isolates with Y132F Mutation in ERG11 Gene,
 447 South Korea. Emerg Infect Dis 2018; 24(9): 1768-70.
- Corzo-Leon DE, Peacock M, Rodriguez-Zulueta P, Salazar-Tamayo GJ,
 MacCallum DM. General hospital outbreak of invasive candidiasis due to
 azole-resistant *Candida parapsilosis* associated with an Erg11 Y132F
 mutation. Med Mycol 2021; 59(7): 664-71.

- 452 14. Fekkar A, Blaize M, Bougle A, et al. Hospital outbreak of fluconazole453 resistant *Candida parapsilosis*: arguments for clonal transmission and
 454 long-term persistence. Antimicrob Agents Chemother 2021.
- 455 15. Govender NP, Patel J, Magobo RE, et al. Emergence of azole-resistant
 456 *Candida parapsilosis* causing bloodstream infection: results from
 457 laboratory-based sentinel surveillance in South Africa. J Antimicrob
 458 Chemother 2016; 71(7): 1994-2004.
- Martini C, Torelli R, de Groot T, et al. Prevalence and Clonal Distribution
 of Azole-Resistant *Candida parapsilosis* Isolates Causing Bloodstream
 Infections in a Large Italian Hospital. Front Cell Infect Microbiol 2020; 10:
 232.
- 463 17. Mesini A, Mikulska M, Giacobbe DR, et al. Changing epidemiology of
 464 candidaemia: Increase in fluconazole-resistant *Candida parapsilosis*.
 465 Mycoses 2020; 63(4): 361-8.
- 18. Demirci-Duarte S, Arikan-Akdagli S, Gulmez D. Species distribution,
 azole resistance and related molecular mechanisms in invasive *Candida parapsilosis* complex isolates: Increase in fluconazole resistance in 21
 years. Mycoses 2021; 64(8): 823-30.
- Thomaz DY, de Almeida JN, Jr., Lima GME, et al. An Azole-Resistant *Candida parapsilosis* Outbreak: Clonal Persistence in the Intensive Care
 Unit of a Brazilian Teaching Hospital. Front Microbiol 2018; 9: 2997.
- Thomaz DY, Del Negro GMB, Ribeiro LB, et al. A Brazilian Inter-Hospital
 Candidemia Outbreak Caused by Fluconazole-Resistant *Candida parapsilosis* in the COVID-19 Era. J Fungi (Basel) 2022; 8(2).
- 476 21. Grossman NT, Pham CD, Cleveland AA, Lockhart SR. Molecular
 477 mechanisms of fluconazole resistance in *Candida parapsilosis* isolates
 478 from a U.S. surveillance system. Antimicrob Agents Chemother 2015;
 479 59(2): 1030-7.
- Thomaz DY, de Almeida JN, Jr., Sejas ONE, et al. Environmental Clonal
 Spread of Azole-Resistant *Candida parapsilosis* with Erg11-Y132F
 Mutation Causing a Large Candidemia Outbreak in a Brazilian Cancer
 Referral Center. J Fungi (Basel) 2021; 7(4).
- White T, Bruns T, Lee S, Taylor J. Amplification and direct sequencing of
 fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gefland

- 486 DH, Sninsky JJ, White TJ. PCR protocols: a guide to methods and 487 applications. San Diego, CA: Academic Press, 1990.
- Arendrup MC, Meletiadis J, Mouton JW, et al. EUCAST technical note on
 isavuconazole breakpoints for *Aspergillus*, itraconazole breakpoints for *Candida* and updates for the antifungal susceptibility testing method
 documents. Clin Microbiol Infect 2016; 22(6): 571 e1-4.
- Diab-Elschahawi M, Forstner C, Hagen F, et al. Microsatellite genotyping
 clarified conspicuous accumulation of *Candida parapsilosis* at a
 cardiothoracic surgery intensive care unit. J Clin Microbiol 2012; 50(11):
 3422-6.
- Singh A, Singh PK, de Groot T, et al. Emergence of clonal fluconazoleresistant *Candida parapsilosis* clinical isolates in a multicentre laboratorybased surveillance study in India. J Antimicrob Chemother 2019; 74(5):
 1260-8.
- Xisto MI, Caramalho RD, Rocha DA, et al. Pan-azole-resistant *Candida tropicalis* carrying homozygous erg11 mutations at position K143R: a
 new emerging superbug? J Antimicrob Chemother 2017; 72(4): 988-92.
- Arastehfar A, Hilmioglu-Polat S, Daneshnia F, et al. Clonal Candidemia
 Outbreak by *Candida parapsilosis* Carrying Y132F in Turkey: Evolution
 of a Persisting Challenge. Front Cell Infect Microbiol 2021; 11: 676177.
- Alcoceba E, Gomez A, Lara-Esbri P, et al. Fluconazole-resistant *Candida parapsilosis* clonally related genotypes: first report proving the presence
 of endemic isolates harbouring the Y132F ERG11 gene substitution in
 Spain. Clin Microbiol Infect 2022.
- 30. Peman J, Canton E, Quindos G, et al. Epidemiology, species distribution
 and in vitro antifungal susceptibility of fungaemia in a Spanish
 multicentre prospective survey. J Antimicrob Chemother 2012; 67(5):
 1181-7.
- S14 31. Canton E, Peman J, Quindos G, et al. Prospective multicenter study of
 the epidemiology, molecular identification, and antifungal susceptibility of *Candida parapsilosis, Candida orthopsilosis,* and *Candida metapsilosis*isolated from patients with candidemia. Antimicrob Agents Chemother
 2011; 55(12): 5590-6.

- Sturdy A, Basarab M, Cotter M, et al. Severe COVID-19 and healthcareassociated infections on the ICU: time to remember the basics? J Hosp
 Infect 2020; 105(4): 593-5.
- 33. Abelenda-Alonso G, Puig-Asensio M, Jimenez-Martinez E, et al. Impact
 of the COVID-19 pandemic on infection control practices in a university
 hospital. Infect Control Hosp Epidemiol 2022: 1-8.
- S25 34. Cultrera R, Barozzi A, Libanore M, et al. Co-Infections in Critically III
 Patients with or without COVID-19: A Comparison of Clinical Microbial
 Culture Findings. Int J Environ Res Public Health 2021; 18(8).
- S28 35. Chong WH, Neu KP. Incidence, diagnosis and outcomes of COVID-19associated pulmonary aspergillosis (CAPA): a systematic review. J Hosp
 Infect 2021; 113: 115-29.
- 36. Thompson Iii GR, Cornely OA, Pappas PG, et al. Invasive Aspergillosis
 as an Under-recognized Superinfection in COVID-19. Open Forum Infect
 Dis 2020; 7(7): ofaa242.
- 37. Bartoletti M, Pascale R, Cricca M, et al. Epidemiology of invasive
 pulmonary aspergillosis among COVID-19 intubated patients: a
 prospective study. Clin Infect Dis 2020.
- Singh K, Kumar S, Shastri S, Sudershan A, Mansotra V. Black fungus
 immunosuppressive epidemic with Covid-19 associated mucormycosis
 (zygomycosis): a clinical and diagnostic perspective from India.
 Immunogenetics 2021.
- 39. Ravindra K, Ahlawat A. Five probable factors responsible for COVIDassociated mucormycosis outbreak in India. Int J Infect Dis 2021.
- 543 40. Sahu RK, Salem-Bekhit MM, Bhattacharjee B, et al. Mucormycosis in
 544 Indian COVID-19 Patients: Insight into Its Patho-Genesis, Clinical
 545 Manifestation, and Management Strategies. Antibiotics (Basel) 2021;
 546 10(9).
- 547 41. Segrelles-Calvo G, de SAGR, Llopis-Pastor E, et al. *Candida* spp. co548 infection in COVID-19 patients with severe pneumonia: Prevalence study
 549 and associated risk factors. Respir Med 2021; 188: 106619.
- 42. Arastehfar A, Carvalho A, Nguyen MH, et al. COVID-19-Associated
 Candidiasis (CAC): An Underestimated Complication in the Absence of
 Immunological Predispositions? J Fungi (Basel) 2020; 6(4).

- 43. Roudbary M, Kumar S, Kumar A, Cernakova L, Nikoomanesh F,
 Rodrigues CF. Overview on the Prevalence of Fungal Infections, Immune
 Response, and Microbiome Role in COVID-19 Patients. J Fungi (Basel)
 2021; 7(9).
- 44. Abdoli A, Falahi S, Kenarkoohi A. COVID-19-associated opportunistic
 infections: a snapshot on the current reports. Clin Exp Med 2021.
- 45. Grau S, Hernandez S, Echeverria-Esnal D, et al. Antimicrobial
 Consumption among 66 Acute Care Hospitals in Catalonia: Impact of the
 COVID-19 Pandemic. Antibiotics (Basel) 2021; 10(8).
- 46. Ramos-Martinez A, Pintos-Pascual I, Guinea J, et al. Impact of the
 COVID-19 Pandemic on the Clinical Profile of Candidemia and the
 Incidence of Fungemia Due to Fluconazole-Resistant *Candida parapsilosis*. J Fungi (Basel) 2022; 8(5).
- 566
- 567

568 Figure Legends

569

570 **Figure 1. Geographical distribution of the different genotypes of FLZ-**571 **resistant isolates.** The pie charts denote the distribution of the different 572 genotypes in different tertiary hospitals from different metropolitan areas in 573 Spain.

574

575

Figure 2. Minimal Spanning Tree showing the genetic proximity of susceptible and FLC-resistant isolates from *Candida parapsilosis*. The numbers denote the genotype identified in each group. Straight bold lines denote groups that only differentiate in one marker. These groups are highlighted with the color shadows in the background. Orange: resistant strains; Green: susceptible strains; Blue: susceptible increased exposure (I) strains. For origin and description of the strains in each genotype, see supplemental table 1.

- **Table 1.** Oligonucleotides designed to sequence the *Candida parapsilosis*
- *ERG11* gene (F, forward; R, reverse).

Oligonucleotide name	Sequence (5´- 3´)
01_F_CpERG11	CGTCAAATGTCAGCATCGTC
02_R_CpERG11	TCATTCGAGGTGAGTCAAC
03_F_CpERG11	TGGGTTGGTTCAGCCGTATC
05_F_CpERG11	ACCATCTTCACTGCATCTAG
07_F_CpERG11	GTTGCATTTGGCTGAGAAGC
09_F_CpERG11	CCAAAGGTGTTAGCTCTTCG
10_R_CpERG11	GACATAGGCAAACTGTTCACC
08_R_CpERG11	CCACCTTTACCAGATAAGGC
06_R_CpERG11	GCATACAATTGAGCAAATGAAGC
04_R_CpERG11	CCAAGTACACCGTCATTACTC

Table 2: Distribution of the percentage of MICs to FLUCONAZOLE of *C. parapsilosis* strains received at the SMRL since 2000. The table include the number of strains analysed each year, and the % of susceptible (S), susceptible increased exposure (I) and resistant (R) isolates.

594

		MIC (mg/L)													
		SUS	CEPTI	BLE		I		RE	SISTA	NT					
Year	0.125	0.25	0.5	1	2	4	8	16	32	64	>64	Ν	% S	% I	% R
2000	2	33	35	16	12	2	0	0	0	0	0	43	98	2	0
2001	1	30	53	12	1	3	0	0	0	0	0	74	97	3	0
2002	8	36	48	5	3	0	0	0	0	1	0	80	99	0	1
2003	11	40	41	5	1	0	1	1	0	0	0	115	98	0	2
2004	7	35	44	9	5	0	0	0	0	0	0	75	100	0	0
2005	18	41	32	6	1	0	0	0	1	0	0	82	99	0	1
2006	3	27	49	17	3	1	0	0	0	0	0	71	99	1	0
2007	3	24	56	8	6	0	1	0	0	0	1	71	97	0	3
2008	3	27	55	5	3	1	1	0	2	0	1	92	95	1	4
2009	0	12	78	4	0	0	4	1	0	0	0	73	95	0	5
2010	9	11	64	9	2	0	2	4	0	0	0	55	95	0	5
2011	5	14	59	14	0	0	9	0	0	0	0	22	91	0	9
2012	14	14	50	23	0	0	0	0	0	0	0	22	100	0	0
2013	0	14	57	21	0	0	7	0	0	0	0	14	93	0	7
2014	15	12	46	23	0	0	0	0	0	4	0	26	96	0	4
2015	0	2	61	37	0	0	0	0	0	0	0	46	100	0	0
2016	0	17	48	17	9	4	4	0	0	0	0	23	91	4	4
2017	9	22	39	4	4	4	4	9	4	0	0	23	78	4	17
2018	0	15	85	0	0	0	0	0	0	0	0	13	100	0	0
2019	18	9	9	18	9	9	0	0	9	0	18	11	64	9	27
2020	3	6	20	6	0	2	8	20	12	17	5	66	35	1.5	63.5
2021	3	13	12	1	4	3	10	36	11	5	1	204	33	3	64

595

596

597 Cells in orange: Mode (most frequent value)

598 In yellow: left and right values to the mode

599

600

Table 3: Distribution of the percentage of MIC to VORICONAZOLE of *C. parapsilosis* strains received at the SMRL since 2000. The table include the number of strains analysed each year, and the % of susceptible (S), susceptible increased exposure (I) and resistant (R) isolates.

606

	MIC (mg/L)														
		SUSCEF	PTIBLE		I			RESIS	TANT						
Year	0.016	0.031	0.06	0.125	0.25	0.5	1	2	4	8	>8	Ν	% S	% I	% R
2000	79	14	7	0	0	0	0	0	0	0	0	42	100	0	0
2001	73	23	1	3	0	0	0	0	0	0	0	74	100	0	0
2002	85	14	0	0	0	1	0	0	0	0	0	80	99	0	1
2003	88	11	0	1	0	0	0	0	0	0	0	94	100	0	0
2004	96	4	0	0	0	0	0	0	0	0	0	75	100	0	0
2005	93	6	0	0	1	0	0	0	0	0	0	82	99	1	0
2006	94	4	1	0	0	0	0	0	0	0	0	71	100	0	0
2007	89	6	4	0	0	0	0	0	0	0	1	71	99	0	1
2008	90	4	0	2	0	1	1	1	0	0	0	92	97	0	3
2009	89	5	1	3	1	0	0	0	0	0	0	73	99	1	0
2010	85	4	4	5	2	0	0	0	0	0	0	55	98	2	0
2011	86	9	0	5	0	0	0	0	0	0	0	22	100	0	0
2012	77	18	5	0	0	0	0	0	0	0	0	22	100	0	0
2013	79	14	0	7	0	0	0	0	0	0	0	14	100	0	0
2014	69	23	4	0	0	0	4	0	0	0	0	26	96	0	4
2015	89	9	0	2	0	0	0	0	0	0	0	46	100	0	0
2016	70	13	13	4	0	0	0	0	0	0	0	23	100	0	0
2017	57	26	0	9	0	4	4	0	0	0	0	23	91	0	9
2018	87	0	0	0	0	13	0	0	0	0	0	15	87	0	13
2019	36	36	0	0	0	9	0	18	0	0	0	11	73	0	27
2020	27	8	0	2	2	24	36	2	0	0	0	66	36	2	62
2021	28	2	3	5	25	27	7	1	1	0	0	204	38	25	37

607

608

609 Cells in orange: Mode (most frequent value)

610 In yellow: left and right values to the mode

611

Table 4: Distribution of the percentage of MIC to ITRACONAZOLE of C.

parapsilosis strains received at the SMRL since 2000.

		MIC (mg/L)												
		SUSCE	PTIBLE				RE	SISTAN	NT					
YEAR	0.016	0.031	0.06	0.125	0.25	0.5	1	2	4	8	>8	Ν	% S	% R
2000	58	30	9	2	0	0	0	0	0	0	0	43	100	0
2001	30	55	11	4	0	0	0	0	0	0	0	74	100	0
2002	25	56	18	0	1	0	0	0	0	0	0	80	99	1
2003	50	36	12	1	0	1	0	0	0	0	0	115	99	1
2004	61	31	7	1	0	0	0	0	0	0	0	75	100	0
2005	52	41	6	0	0	0	0	0	0	0	0	82	100	0
2006	73	20	6	1	0	0	0	0	0	0	0	71	100	0
2007	63	25	8	1	0	0	0	0	0	0	1	71	99	1
2008	52	40	4	0	2	1	0	0	0	0	0	92	97	3
2009	78	21	0	1	0	0	0	0	0	0	0	73	100	0
2010	95	0	2	2	2	0	0	0	0	0	0	55	98	2
2011	86	9	5	0	0	0	0	0	0	0	0	22	100	0
2012	95	5	0	0	0	0	0	0	0	0	0	22	100	0
2013	71	29	0	0	0	0	0	0	0	0	0	14	100	0
2014	65	23	4	0	4	4	0	0	0	0	0	26	92	8
2015	72	28	0	0	0	0	0	0	0	0	0	46	100	0
2016	35	22	30	13	0	0	0	0	0	0	0	23	100	0
2017	26	35	22	9	9	0	0	0	0	0	0	23	91	9
2018	7	20	67	7	0	0	0	0	0	0	0	15	100	0
2019	9	18	36	27	9	0	0	0	0	0	0	11	91	9
2020	15	20	41	23	2	0	0	0	0	0	0	66	98	2
2021	23	28	22	20	6	1	1	0	0	0	0	204	89	11

618 Cells in orange: Mode (most frequent value)

619 In yellow: left and right values to the mode

Table 5: Distribution of the percentage of MIC to POSACONAZOLE of C.

parapsilosis strains received at the SMRL since 2000

		MIC (mg/L)												
	SUS	CEPTIE	BLE			RE	SIST	ANT						
YEAR	0.016	0.031	0.06	0.125	0.25	0.5	1	2	4	8	>8	Ν	% S	% R
2001	55	45	0	0	0	0	0	0	0	0	0	11	100	0
2002	65	31	4	0	0	0	0	0	0	0	0	80	100	0
2003	80	19	1	0	0	0	0	0	0	0	0	94	100	0
2004	83	17	0	0	0	0	0	0	0	0	0	75	100	0
2005	65	33	2	0	0	0	0	0	0	0	0	82	100	0
2006	87	13	0	0	0	0	0	0	0	0	0	70	100	0
2007	87	11	0	0	0	0	0	0	1	0	0	71	99	1
2008	70	26	1	1	1	1	0	0	0	0	0	92	97	3
2009	81	19	0	0	0	0	0	0	0	0	0	73	100	0
2010	74	20	2	2	2	0	0	0	0	0	0	54	96	4
2011	95	5	0	0	0	0	0	0	0	0	0	22	100	0
2012	91	9	0	0	0	0	0	0	0	0	0	22	100	0
2013	93	7	0	0	0	0	0	0	0	0	0	14	100	0
2014	92	4	4	0	0	0	0	0	0	0	0	26	100	0
2015	78	20	2	0	0	0	0	0	0	0	0	46	100	0
2016	22	52	22	4	0	0	0	0	0	0	0	23	96	4
2017	26	57	13	4	0	0	0	0	0	0	0	23	96	4
2018	13	47	33	7	0	0	0	0	0	0	0	15	93	7
2019	18	36	36	9	0	0	0	0	0	0	0	11	91	9
2020	35	39	23	3	0	0	0	0	0	0	0	66	97	3
2021	23	38	20	12	4	2	1	0	0	0	0	204	81	19

628 Cells in orange: Mode (most frequent value)

629 In yellow: left and right values to the mode

Table 6: Distribution of the percentage of MIC to ISAVUCONAZOLE of C.

parapsilosis strains received at the SMRL since 2016

	MIC (mg/L)													
YEAR	0.016	0.031	0.06	0.125	0.25	0.5	1	2	4	8	>8	Ν		
2016	86	14	0	0	0	0	0	0	0	0	0	7		
2017	75	15	5	0	5	0	0	0	0	0	0	20		
2018	87	7	7	0	0	0	0	0	0	0	0	15		
2019	64	18	9	0	0	9	0	0	0	0	0	11		
2020	30	14	41	9	0	0	0	0	0	0	0	62		
2021	38	23	29	7	2	1	1	0	0	0	0	196		

637 Cells in orange: Mode (most frequent value)

638 In yellow: left and right values to the mode

Table 7. Mutations in the *ERG11* gene found in susceptible, susceptible
increased exposure (I) and resistant strains to fluconazole. For each
category, we also include the susceptibility profile (S/I/R) for voriconazole. HET:
heterozygous; HOMO: homozygous.

<i>ERG11</i> Mutation	FLC Susceptible	Susce	FLC ptible inc exposure	reased	FLC Resistant				
	VOR_S	VOR_S	VOR_I	VOR_R	VOR_S	VOR_I	VOR_R		
WT	34	1	1	0	5	1	6		
Y132F_HET	0	3	1	0	1	17	38		
Y132F_HOMO	0	0	0	1	5	29	87		

Table 8. Susceptibility profile of WT or mutant strains harboring the Y132F

656 in homozygosity (HOMO) or heterozygosity (HET).

			An	tifungal susc	eptibity (mg	J/L)
Antifungal	ERG11 mutation	N	Median	Geometric Mean	Minimal	Maximal
	WT	43	0.5	0.78	0.125	>64
Fluconazole	Y132F_HET	57	16	12.5	4	32
	Y132F_HOM	108	16	26.1	16	>64
	WT	43	0.031	0.032	0.016	4
Voriconazole	Y132F_HET	57	0.5	0.39	0.125	1
	Y132F_HOM	108	0.5	0.5	0.06	2
	WT	43	0.03	0.033	0.016	1
Itraconazole	Y132F_HET	57	0.125	0.10	0.031	0.25
	Y132F_HOM	108	0.06	0.05	0.016	0.25
	WT	43	0.03	0.029	0.016	0.25
Posaconazole	Y132F_HET	57	0.06	0.065	0.016	0.5
	Y132F_HOM	108	0.031	0.035	0.016	0.125
	WT	43	0.016	0.021	0.016	1
Isavuconazole	Y132F_HET	57	0.06	0.067	0.031	0.125
	Y132F_HOM	108	0.031	0.039	0.016	0.5



